B-Cell Non-Hodgkin Lymphoma | Norton Healthcare

Indication: B-Cell Non-Hodgkin Lymphoma

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Teneobio, Inc.

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.